{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:54:48Z","timestamp":1789224888173,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Benign familial pemphigus (BFP) is a chronic autosomal dominant genodermatosis characterized by the appearance of flaccid blisters that progress to painful erythematous macerated plaques and erosions in intertriginous areas. Although various treatments for BFP exist, current treatments are not consistently effective, and BFP symptoms often cause a decreased quality of life. We report a case series of three patients with refractory moderate-to-severe BFP who were successfully treated with dupilumab. We also describe their clinical evolution over a follow-up period of 18\u2005months. All patients reported a decrease in pruritus and improved skin findings, with no adverse side-effects. However, increased dosing was required in one patient to achieve optimal control of the disease. We also discuss previously reported cases of BFP treated with biologics. Dupilumab appears to be a useful and safe treatment option for patients with refractory BFP.<\/jats:p>","DOI":"10.1093\/ced\/llae507","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:28:42Z","timestamp":1733876922000},"page":"841-844","source":"Crossref","is-referenced-by-count":2,"title":["Refractory benign familial pemphigus successfully treated with dupilumab: a case series"],"prefix":"10.1093","volume":"50","author":[{"given":"Ana","family":"Simon Gozalbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mauleon Fernandez","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Carrascosa de Lome","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A","family":"Martin Diaz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"de la Cueva Dobao","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"2025032702501725800_llae507-B1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/hmg\/9.7.1131","article-title":"Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca(2+) pump","volume":"9","author":"Sudbrak","year":"2000","journal-title":"Hum Mol Genet"},{"key":"2025032702501725800_llae507-B2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/ijd.16322","article-title":"A case of Hailey-Hailey disease successfully treated with dupilumab","volume":"61","author":"Licata","year":"2022","journal-title":"Int J Dermatol"},{"key":"2025032702501725800_llae507-B3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40257-019-00477-z","article-title":"Hailey-Hailey disease: an update review with a focus on treatment data","volume":"21","author":"Ben Lagha","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2025032702501725800_llae507-B4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjd.20475","article-title":"Hailey-Hailey disease treated with dupilumab: a case series","volume":"185","author":"Alzahrani","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025032702501725800_llae507-B5","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.jid.2020.12.026","article-title":"SMOC1 and IL-4 and IL-13 cytokines interfere with Ca2+ mobilization in primary human keratinocytes","volume":"141","author":"Lyubchenko","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2025032702501725800_llae507-B6","doi-asserted-by":"crossref","first-page":"e776","DOI":"10.1111\/jdv.18350","article-title":"Dupilumab in Hailey-Hailey disease: a case series","volume":"36","author":"Alamon-Reig","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025032702501725800_llae507-B7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ced\/llae298","article-title":"Treatment of Hailey\u2013Hailey disease with biologics and small-molecule inhibitors: a systematic review","volume":"50","author":"Liu","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2025032702501725800_llae507-B8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jdcr.2023.09.011","article-title":"Refractory Hailey-Hailey disease cleared with upadacitinib","volume":"41","author":"Murphy","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2025032702501725800_llae507-B9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ced\/llad023","article-title":"Improvement of Hailey-Hailey disease with abrocitinib","volume":"48","author":"Li","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2025032702501725800_llae507-B10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jdcr.2023.10.004","article-title":"Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab","volume":"42","author":"Khang","year":"2023","journal-title":"JAAD Case Rep"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae507\/61007688\/llae507.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/4\/841\/61007688\/llae507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/4\/841\/61007688\/llae507.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T04:33:54Z","timestamp":1743309234000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/4\/841\/7919673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2025,3,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae507","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,12,10]]}}}